ADC Therapeutics Plans Exciting Update on LOTIS-7 Clinical Trial
ADC Therapeutics SA (NYSE: ADCT) has recently announced its intention to provide an important update regarding the LOTIS-7 clinical trial. This Phase 1b open-label study is investigating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab for patients battling relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
The corporate update will be shared during a conference call as well as a live webcast, scheduled to take place in a near future. Investors and interested parties have the opportunity to tune in and learn about the promising developments emerging from this pivotal trial.
Event Details for the Corporate Update
During the conference call, which will occur live, participants will gain insights into the preliminary data collected from this significant clinical trial. It is advised for those wishing to join the call to register ahead of time, ensuring they do not miss the valuable information that will be discussed.
Furthermore, a streamed version of the call will be available for later viewing, making it convenient for stakeholders to access the information at their leisure.
Understanding the LOTIS-7 Clinical Trial
The LOTIS-7 clinical trial represents an innovative approach in the treatment landscape for patients with hematological malignancies, particularly those with DLBCL. ADC Therapeutics has positioned itself at the forefront of this advancement with its proprietary ADC technology.
ZYNLONTA, which has already received accelerated approval from regulatory bodies, is notable for its role in treating patients who have previously undergone multiple lines of systemic therapy. The inclusion of the bispecific antibody glofitamab in the treatment regimen exemplifies a strategic approach to augmenting the efficacy of therapy in this patient population.
Company's Commitment to Innovative Cancer Therapies
ADC Therapeutics remains dedicated to revolutionizing oncology treatment through its innovative research and development efforts. The ongoing evolution of their ADC technology aims to provide enhanced therapeutic options for patients, contributing to improved survival rates and quality of life.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is recognized as a pioneering leader in the creation and application of antibody drug conjugates. The company's focus is on advancing therapies that target and treat hematologic cancers and solid tumors, significantly contributing to the medical field's understanding and management of these complex diseases.
With its headquarters located in Lausanne, Switzerland, ADC Therapeutics is strategically positioned to engage in collaborations that foster innovation. Their existing product, ZYNLONTA, exemplifies their commitment to seeking new frontiers in treatment efficacy and safety.
Future Prospects and Developments
In addition to ZYNLONTA, ADC Therapeutics is actively pursuing multiple ADC candidates that are currently in clinical and preclinical stages of development. The progress made in these areas is indicative of the company's unwavering pursuit of advancements that can ultimately transform patient care.
Frequently Asked Questions
What is the purpose of the LOTIS-7 clinical trial?
The LOTIS-7 clinical trial aims to evaluate the safety and efficacy of the combination therapy ZYNLONTA and glofitamab in treating relapsed or refractory diffuse large B-cell lymphoma.
When will the update on the trial be available?
The update will be announced during a conference call and live webcast set to take place in the near future.
How can I access the conference call?
Interested participants can register for the conference call ahead of time to access the live discussion regarding the trial's findings.
What sets ZYNLONTA apart from other treatments?
ZYNLONTA is an antibody drug conjugate that received accelerated approval from the FDA, specifically targeting and treating DLBCL, which sets it apart in therapeutic options for this condition.
Is ADC Therapeutics planning further research?
Yes, ADC Therapeutics is actively engaged in ongoing research and development for multiple ADC therapies, aiming to push the boundaries of cancer treatment.
